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1. Introduction
Lung cancer is the leading cause of cancer deaths in both men and women, with more than 1
million deaths worldwide each year [1]. Unfortunately, this difficult therapeutic area has
shown the highest failure rate in clinical trials over the last 30 years [2] and hitherto, there is
no effective treatment for patients with lung cancer. The reasons for this drug attrition are
multiple, but one major explanation is considered to be the lack of relevant preclinical models
to appropriately validate potential drug targets and rank novel therapeutic agents before
engaging in clinical trials [3].
Genetically engineered mice, ectopic and orthotopic xenotransplantation of tumors into
immunodeficient mice are common models used as surrogate of patients to evaluate drug
candidates before clinical testing. Although animal models can recapitulate important facets
of human responses, their limitations as preclinical cancer models have now been widely
documented [4-7]. Fundamental differences in transcriptional regulation [8], telomerase
activity [9], neoplastic transformation mechanisms [10], cytokines production [11] as well as
matrix metalloproteinases biology [12] are but a few features which compromise the design of
efficient cancer therapies. Even the patient derived xenograft model (PDX), which better
recapitulate the phenotypic features of the human tumor, displays a number of inherent
limitations [13]. In this system, the tumorgraft established from primary tumor fragments has
to be maintained through serial transplantations into mice, which will lead to the loss of the
human stroma environment after 2-3 passages [14]. Clearly, such a replacement of the original
tumor microenvironment by murine host components has significant consequences on growth
features as well as response to therapies. Indeed, a number of oncogenic mouse ligands fail to
cross-activate their related human receptors [15, 16] while stromal mediators have been
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identified as a critical source triggering tumour cells resistance to treatment [17, 18]. These
observations highlight the importance of considering tumor-extracellular matrix interactions
in the design of in vitro cancer models. Modern tumor biology has moved away from the
traditionalist view conveyed for years by 2D cultures saturated with growth factors by
revealing that the many varieties of cells that compose a tumor don’t just grow on their own
but constantly integrate and react to signals coming from the extracellular matrix components.
Solid tumors are now regarded as complex organs able to instruct the surrounding tissue to
promote their own growth and progression, but also dependent on both molecular and
mechanical signals coming from the adjacent healthy environment [19, 20]. Therefore,
experimental models recapitulating true human cancer biology are mandatory for the
validation of therapeutic agents in order to keep away from the risk of studying no more than
adaptive cancer biology in a wrong environment that will eventually result in translation
failure.
Figure 1. (A) Cancer deaths anticipated in 2014. Estimated leading cancer sites mortality in European Union for the
year 2014 expressed as percent of total cancer deaths. Column diagram highlights the mortality rate within the popula‐
tion specifically affected by lung cancer. (B) Age-standardized (world population) EU male (blue) and female (red)
lung cancer death rates per 100,000 from 1982 to 2014. The graph shows the unfavourable trend for female lung cancer
with a regular increase in case numbers over the last 30 years. Source: Malvezzi et al, Annals of oncology, 2014; 25(8):
1650-6. and Bosetti et al, Annals of oncology, 19: 631–640, 2008.
In this article we report the significant efforts ongoing within academia and industry to
developing in vitro novel complex human tumor models that should improve the identification
and selection of efficient lung cancer therapies. We first focus on the human lung cancer cell
lines currently available, their contribution to lung cancer biology and their use in research.
Then, we will move from cell monolayers to three-dimensional (3D) cultures, exploring at first
the function of natural and synthetic extracellular matrix before to document some recent
advances in the field, including spheroids, bioscaffolds, decellularized lung matrix models and
precision-cut lung tumor slices. Finally, we will present the bioengineering of a new generation
of lung cancer models: OncoCilAir™. These 100% human models, which combine in vitro both
tumor nodules surrounded by a functional airway epithelium and stroma, open new ways to
test simultaneously drug efficacy, side toxicity and tumor recurrence in a single, integrated
and accessible 3D model.
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2. Lung cancer, current treatments and perspectives
Lung cancer (LC) is one of the major health concerns in the western world. LC is the most
frequently diagnosed cancer in men and women and represents the most common cause of
cancer-related deaths, both in the United States and in Europe, with a significant rate of 27%
and 21% of total cancer deaths, respectively [21] (Fig.1A). The LC epidemic has been clearly
linked to tobacco smoking [22], and while mortality rate in men has regularly fallen over the
last decades (53 lung cancer deaths for every 100,000 European males in the late 1980s to
41.1/100,000 in 2009) thanks to strong measures for smoking control and prevention in middle-
aged men, female LC rates are predicted to rise 8% in 2015 [1] (Fig.1B). There are two main
types of lung cancer: non-small lung cancer (NSCLC) which account for about 85% of all lung
cancers and small cell lung cancer (SCLC, 15%). SCLC is the most aggressive form of LC, with
fast growing cells leading to large tumors. Histologically, NSCLC includes 3 subgroups:
adenocarcinoma, squamous cell and large cell carcinoma [23]. As in many other forms of
cancer, LC does not display too many symptoms, develops slowly over a period of several
years, and only manifests itself in advanced stages (III or IV), where five-year survival rates
are less than 10% because of high degree of metastasis. The overall median survival in stage
IV is only about 8-10 months [24]. Platinum and taxane based chemotherapies (cisplatin,
paclitaxel) has remained for years the treatments of choice, but more recently LC patients have
been selected based on their tumor mutation profile. In most cases, oncogene driver mutations
are exclusives (EGFR, ALK/EML4, KRAS, PTEN, etc...) and importantly, they divided patient
populations into molecular subsets that do not show the same sensitivity to different treat‐
ments [25]. This patient stratification has enabled the introduction of targeted therapies
directed against specific signaling pathways whose tumors are dependent on. Indeed,
humanized recombinant antibodies directed against the vascular endothelial growth factor
(VEGF) (bevacizumab) or small molecule inhibitors of EGFR-TK (erlotinib, gefitinib and
afatinib), ALK and MET (crizotinib, ceritinib) have recently been used as a promising new line
of therapies to treat lung cancer. Unfortunately, this drug portfolio extends survival only by
a few months (Table 1) since most of the patients develop resistance to treatments, leading
invariably to the recurrence of the disease [26-32]. Huge efforts are now undertaken to
understand and circumvent drug resistance mechanisms. First observations have pointed out
two main mechanisms for drug resistance acquisition: the selection of another pre-existing
oncogene mutation or the activation of a bypass track, i.e. the deregulation of an alternative
growth signaling pathway to maintain cell proliferation and tumor progression [33]. In
EGFR-mutant lung cancer treated with the EGFR-TK inhibitors erlotinib and gefitinib,
resistance is generally mediated by the T790M EGFR second-site mutation (~50% of the cases)
[34] or phosphatidylinositol 3-kinase PI3K–AKT pathway activation via focal amplification of
MET as second signaling pathway (~5%) [35]. For ALK-mutant lung cancer treated with
crizotinib, mechanisms of resistance include the gatekeeper mutation L1196M (~30% of the
cases) and KIT and EGFR signaling pathways activation as bypass track (~45%) [36]. Overall,
these findings argue for the use of combined therapies in a manageable way. But recent data
based on the analysis of tumor specimens at the time of acquired resistance suggest a much
more complex landscape. In fact, multiple mechanisms, as diverse as epigenetic changes [37],
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epithelial to mesenchyme transition (EMT) or conversion from a LC histological type to
another (EGFR-dependent NSCLC to SCLC), are induced under the selective pressure of
targeted therapies [38, 39]. These observations imply the arrival of a personalized medicine,
where a careful profiling of patient tumor’s mutation status (germline and somatic) and
epigenetic signature will be mandatory all along the therapy to identify and adapt the correct
treatment strategy. However, such scheduled combinatorial regimen would require the
development of multiple-generation inhibitors to overcome specific subsets of resistance
mutations and induce durable remissions. But the ability to escape multiple types of treatment
could well be a hallmark of cancer cells. With this in mind, alternative strategies are worth
considering. Instead of constraining tumor cells signalling through exogenous therapies
making them overreact, a different approach might be to restrict tumor progression through
its own microenvironment. The original 1975’s experiment of teratocarcinoma injection into
blastocysts from Mintz and Illmensee was the first example of tumor repression by the
microenvironment [40]. Today, tumor reprogramming through stroma instruction is emerging
as a new treatment paradigm [41-43]. From this perspective, advanced human three-dimen‐
sional (3D) cell culture approaches modelling tumor-stroma communication could be key to
accelerate the development of new lung cancer therapeutics.
Table 1. Targeted therapies approved by the Food and Drug Administration in the treatment of lung cancer. The
median time to progression on targeted therapy (Progression Free Survival - PFS) is given in months. rHMAb:
recombinant human monoclonal antibody. Source: National Cancer Institute database, 2014.
3. Lung cancer cell lines
Cell lines derived from human tumors provide an unlimited, self-replicating source of
malignant cells that can be studied by investigators throughout the world. Therefore, even if
cell lines represent only a highly selected fraction of the original tumor, their ease of access has
resulted in the production of a very large body of literature. Indeed, it is acknowledged that
most of our understanding of the molecular mechanisms involved in LC comes from studies
done on mouse or human cell lines [44].
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3.1. Lung cancer cell lines collection
To date, more than 250 LC cell lines have been established, mainly from Western population.
Currently, the American Type Culture Collection (ATCC, Manassas, VA) catalog lists 121
human lung tumor cell lines. Among this panel, SCLC is less represented, first due to the lower
frequency of the disease, and second because SCLC tumors are rarely surgically resected.
Indeed, only small tissue samples from biopsy examinations, malignant aspirates, and rare
malignant effusions are available for research use. Moreover, the fact that SCLC tumor cells
lack the ability to adhere to culture dishes and required to be grown in vitro as floating cell
aggregates or spheroids has precluded for a long time their expansion as cell lines. SCLC was
first successfully cultured in Japan in 1971 [45].
Regarding NSCLC, primary and metastatic tumor materials are more easily accessible, even
through routine bronchoscopy [38, 39]. However, although cells from metastatic tumors,
especially from malignant effusions, are relatively easy to culture, cell cultures from primary
solid tumor are not obvious to establish, with success rates ranging from 2.6 to 5% [46, 47].
Various protocols are in use, but on the whole, tumor tissues minced in small pieces are either
directly cultured as fragments in a matrix (e.g. Matrigel®) or subjected to enzymatic dissoci‐
ation (collagenase/hyaluronidase) and then suspended in culture medium. Clearly, positive
results are higher when starting from material corresponding to advanced stages as MHC III
and IV [46]. The culture medium composition is also critical and the development of serum-
free chemically defined media (e.g. ACL4) has significantly improved success rates [48].
The resulting current LC cell lines depository represent therefore a unique resource that can
be extremely valuable in term of genetic manipulation, high-throughput screening and
development of more complex co-culture models.
3.2. Lung cancer cell lines as in vitro model
LC cell lines have been used for decades in functional studies with the aim to identify new
oncogene drivers or tumor suppressors. Thus, LC cell lines compared to normal human
bronchial epithelial cells were instrumental to generate list of differentially expressed genes
that could account for tumorigenicity and represent therefore new therapeutic targets. As an
example, this strategy lead to the detection of ERBB3, a gene associated with the EGF signaling
pathway, among the genes over-expressed in LC cell lines [49]. Interestingly, this result was
validated later on by another study that identified the activation of ERBB3 signaling as a
mechanism of resistance to gefitinib [35]. Since these initial findings, ERBB3 has been recog‐
nized as a key node of LC progression and several humanized anti-ErbB3 antibodies are
currently in pre-clinical development [50].
However, cell lines limitations have emerged as our knowledge about the disease increased.
As an example, several studies have shown that differences in genetic background are
important in defining cancer biology as well as in drug sensitivity [51]. Thus, a potential
shortcoming of the current LC collection may reside in its under-representation of some
populations, like the East Asian population, possibly introducing bias in research and drug
discovery. Indeed, epidemiologic surveys have revealed that in the US, 10% of patients with
NSCLC have tumour associated with EGFR mutations, while this number increases to 35% in
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East Asia, suggesting different selection mechanisms or sensitivity for lung cancer subtypes
among different ethnic groups.
Accordingly, the recent classification of lung cancers into genetic subsets based on mutations
in driver oncogenes (see previous section) prompted the community to accurately characterize
the LC cell lines collection at the genomic and genetic levels. In this perspective, the Sanger
Cancer Institute has initiated the genetic characterization of a panel of cancer cell lines (The
Cancer Genome Project, http://cancer.sanger.ac.uk/cancergenome/projects/cell_lines/). Using
current high throughput techniques this program provides information on mutations, copy
number variations, single nucleotide polymorphisms (SNPs) and microsatellite instability of
136 cell lines representative of the different type of lung cancers (adenocarcinoma, small cell
carcinoma, etc...) with the aim to define a genetic profile predictive of drug sensitivity. Such a
signature should contribute to stratify patient population and to identify efficient targeted
therapies.
Another emerging use of LC cell line is related to the identification of resistance mechanisms.
As documented in section 2, so far all the approaches used in the treatment of lung cancer have
resulted in the acquisition of resistance by the patients. One successful approach to discovering
resistance mechanisms has been to culture sensitive cell lines with increasing concentrations
of the drug until resistance emerges. The resistant cell line can subsequently be analysed to
identify the resistance mechanisms, leading to the identification of resistance biomarkers and
new strategies to overcome resistance [36].
Undoubtedly, cell lines have proven to be useful in elucidating important aspect of lung cancer
biology. However, thanks to modern deep-sequencing technologies, we now know that lung
tumors are composed of population of cells with distinct molecular and phenotypic properties
[52] and consequently, that cell lines do not fully recapitulate human tumor biology. Clearly,
the scientific community has taken into account these limitations, as shown by the growing
interest for the establishment of complex in vitro cell models intended to bridge the gap
between animal models and human studies.
4. Biocompatible matrices for 3D cell culture
In this section, we will try to briefly resume different ways and techniques used to culture the
cells in 3D. Maintaining a 3D structure is critical to reproduce the tumour-stroma environment,
communication between tumour cells, and the interaction with other surrounding cell types
such as epithelial cells or fibroblasts [19]. Advances in materials chemistry and processing
technologies, as well as developmental biology have led to the design of 3D cell culture
matrices and bioscaffolds that better represent the geometry, chemistry, and signaling
environment of natural extracellular matrix.
To obtain 3D cell cultures, cells are generally seeded onto/into biocompatible scaffolds or
matrices. The 3D differentiation of cells depends on various parameters but it is generally
accepted that best results are obtained when the natural environment is closely imitated [53].
Natural extracellular matrices are mainly composed of fibrous network made of collagen,
elastic fibers, water and other materials like glycosaminoglycans, proteoglycans and glyco‐
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proteins [54]. To mimic the natural extracellular environment of the cells important parameters
have to be taken into account [55]:
1. The matrix composition (collagen, fibrin, alginate, etc.)
2. The structure (pore size, pore distribution, pore geometry, etc.)
3. The manufacturing method (electrospinning, 3D printing, inverted colloidal crystal,
spontaneous polymerization, etc.)
4. The biocompatibility
As the fate of a cell is largely determined by its environment, the elaboration of the right
extracellular context is critical to promote the correct differentiation of a cell population.
For example, it is well known that epithelial cells have to be cultured at the air-liquid interface
to differentiate. This could be easily obtained by seeding cells onto micro porous supports or
scaffolds allowing nutrients to come from the back. The apical side of the cells remains
generally exposed to the air [56]. This basic principle of air-liquid interface cultivation can be
transposed to most of epithelial cells such as airway, vaginal, buccal, intestinal, etc. However,
this approach is no more suitable when the cells are not from epithelial origin [57, 58].
It is typically the case for fibroblasts that are not able to survive when directly exposed to the
air. To culture fibroblasts in 3D, a different type of environment is required. Cells can be
embedded into a biocompatible matrix based on various components [53]. Among the most
used we find collagen and fibrin. Collagen is the major component of connective tissues, it is
naturally produced by fibroblasts and can be easily isolated from many type of tissues such
as dermis, bone, tendon, etc...
Whereas collagen is easily obtained, applications for human therapies and 3D cell culture
remain limited because of contamination risks between animals and humans (e.g. Creutzfeldt-
Jakob). Moreover, the gel polymerization can be difficult to control thus reducing the field of
applicability. Another drawback is the variation between batches to batches. These weaknesses
have led to the development of new generations of synthetic matrices and scaffolds where
polymerization as well as intrinsic properties of materials (elasticity, porosity, permeability,
hydration, etc.) can be more easily controlled. The matrices used today for 3D cell culture can
be divided into 3 groups:
a. Natural compounds: collagen, gelatin, hyaluronate, glycosaminoglycan, chitosan,
alginate, silk, fibrin, dextran, matrigel®, etc...
b. Synthetic compounds: polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-
glycolic acid (PLGA), polycarpolactone (PCL), polyethylene glycol (PEG), polyvinyl
alcohol (PVA), polypropylene fumarate (PPF), polyacrylic acid (PAA), etc...
c. Mixed compounds, made of natural compounds synthetically modified. These included
peptide-coupled alginates, chitosan, hyluranan, tyrosine-derived polymers, etc...
Each material has its own strengths and weaknesses and therefore it is fundamental to select
matrix components in function of the needs. In the context of lung tumor cell model, it is
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pertinent to determine the final end-point studied. For example, if cells invasion has to be
studied, it is necessary to use matrix components where cells are able to adhere, migrate and
proliferate [59]. Moreover, some cells have the ability to digest and transform the scaffold and
elaborate a new environment adapted to their needs. In that case it will be valuable to select a
natural matrix component like collagen or fibrin. If the goal of the experiment is to obtain a 3D
scaffold for human therapy, the best choice will be the use of synthetic matrices where all
components can be defined and controlled [60]. If the sensitivity of a cancer cell to a drug has
to be studied, a relevant choice could be the use of cell spheroids embedded into a non
degradable matrix component, like alginate [61]. In that case, cells are immobilized and their
drug susceptibility can be determined using a simple viability test. Alginate scaffold has been
optimized for 3D tumor modeling using H460, A549 and H1650 NSCLC cell lines [62]. In this
study the anticancer effects of various chemotherapeutic agents were studied and compared
with conventional 2D cell culture models. Results have shown that cells grown in 3D demon‐
strated a more realistic drug response with higher resistance to chemotherapy [62].
Clearly, there is a tremendous flexibility to reconstitute a scaffold and the choice of synthesis
should be guided by the type of cells, the application and the desired physical properties [53].
In addition, new perspectives are offered by bioprinting technologies. The possibility to
organize extracellular matrix into precise geometries should help engineering 3D complex
tumor tissues for in vitro assays [63].
5. Tumor spheroid models for lung cancer research
Numerous anchorage-independent assays have been developed for drug discovery. The most
popular is the spheroid model because it allows both 3D self-organization of tumor cells and
drug screening in high-throughput format. Many normal and malignant cell types can be
grown as sphere-shaped cell colonies, so called spheroids. Cells that don’t form spheroids
spontaneously can be induced to do so by co-culturing with spheroid-forming non-clonogenic
feeder cells [64]. As spheroid environment can be controlled, effects on tumor cell viability can
be carefully examined. This model is particularly adapted to high throughput screening in 96-
well plate assays, and numerous solutions are commercially available.
Phenotypic and functional differences between lung tumor cells grown as 2D monolayer
cultures, versus cells grown as 3D spheroids have been observed. Indeed, the 3D spheroid
culture changed the cellular response to drugs and growth factors suggesting to be more
accurately mimicking the natural tumor microenvironment than classical culture of lung cell
line [65]. Multi-cell type tumor spheroids are a valuable model to reproduce cellular hetero‐
geneity and provide more comprehensive assessment of tumor response to therapeutic
strategies. 3D co-culture model using NSCLC cell lines in combination with lung fibroblasts
can be prepared [66]. To date, co-cultures involving up to three different cell types in a single
spheroid (tumor cells, fibroblasts and endothelial cells) have been established, but without any
proof of micro-capillary functionality [67]. Recent studies report that NSCLC can acquire
epithelial-mesenchymal transition and cancer stem-like phenotypes within chitosan-hyalur‐
onan membrane-derived 3D tumor spheroids [68].
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6. Microfluidic chip-based 3D co-cultures
In the continuity of the pioneering work of Donald Ingber (organ on chip), a series of 3D lung-
on-a-chip microfluidic devices have been developed. Briefly, lung-on-a-chip is a biomimetic
microsystem that reconstitutes the critical functional alveolar-capillary interface of the human
lung, with periodic mechanical stretching and flow of the medium carrying immune cells.
Using this micro-fluidic device, the authors were able to replicating the immune responses
against bacterial infections in vitro [69]. Afterwards, devices were optimized as a drug
screening platform to select individualized treatment for lung cancer. In these systems, lung
cancer and stromal cell lines were co-cultured as 3D spheroids under continuous media
supplementation, mimicking the circulation of nutrients and metabolic waste out of the
cultures [70]. Another similar model has been developed for chemoresistive testing of pleural
mesothelioma cancer spheroids. Interestingly, growth inhibitory concentration of cisplatin
showed higher concentration in perfused tumor spheroids compared with spheroids cultured
under static conditions [71]. These systems represent therefore valuable tools to get informa‐
tion about the efficacy of chemotherapeutic drugs in a dynamic microenvironment which
recapitulate the actual in vivo situation, but they do not address side-toxicity on normal lung
physiology. The challenge will be to improve the model so that it incorporates normal and
functional tissues. That could be achieved by connecting such devices with other microphy‐
siological organotypic chips, representative of healthy lung tissues.
7. Ex vivo 3D lung cancer model based on decellularized matrix
As it is not obvious to identify the ideal matrix components and conditions suitable for the
development of various lung tumor types, an alternative strategy is to take advantage of
existing natural matrices. This methodology relies on the initial work of Ott and colleagues
that first succeed in regenerating a bioartificial organ from a rat cadaveric lung [72]. Briefly, in
this model the organ of interest is perfused with a detergent in order to remove donor cells
and leave the components of the extracellular matrix. The resulting decellularized matrix is
then reloaded with human lung adenocarcinoma tumor cells. In addition to their well-adapted
composition, decellularized matrices also display specific elasticity which has been pointed
out as critical for tumor cell growth. To date, rat decellularized lung matrix [73] and porcine
decellularized intestinal submucosa [17] have been used as scaffold. Interestingly, tumor cell
lines (A549, H460 and H1299) engrafted in this microenvironment formed 3D lung tumor
nodules and displayed histological features reminiscent of the original primary tumor [74].
They also recovered functionalities (e.g. MMP-9 production) that were lost in 2D culture [73].
These ex vivo 3D models can be kept in culture for up to 28 days and exhibit sensitivity to
treatment comparable to what is observed in clinic [17]. Although relevant for fundamental
research, current ex vivo 3D lung models clearly show limitations. First, they are difficult to
produce, the cultivation of the cells must take place in a special incubator, and consequently
they cannot be used for high-throughput screening. Second, they do not recapitulate the
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human – human interactions between tumor and stroma. Indeed, epithelial and mesenchymal
cells have been removed from epithelial space by the decellularization process. Third, they
necessitate large amount of tumor cells (~25 millions) in order to colonize the matrix, preclud‐
ing personalized medicine. And finally, they required the sacrifice of animals for matrix
supply. However, ex vivo 3D lung models must be seen as the gold standard to be reached by
3D bioprinting technologies combined to synthetic matrices.
8. Precision-cut lung tumor slices
As previously mentioned, the tumor microenvironment provides essential signaling necessary
for establishing and maintaining tumor specific morphogenic programs. Precision-cut lung
slices (PCLS) obtained from freshly isolated human lung cancer tissues maintain both the
original cancer microenvironment and preserve the complexity of the tumor-stroma interac‐
tion [75, 76]. Usually thin tissue slices (~200 µM) are prepared with a vibratome and cultured
submerged into medium for several days. PCLS constitute a valid tool for the in vitro evaluation
of tumor morphology, proliferation, viability and resistance to therapy [75]. Moreover, a major
advantage of this model is the preparation of multiple experimental replicates from a single
tumor, allowing performing drug efficacy studies. Indeed, dose-response experiments with
the PIK3 inhibitor LY294002 have shown that PCLS cultures from lung cancer may be used to
predict tumor sensitivity to drugs in a patient-specific manner [75]. In a different study, tumor
PCLS were used to investigate nanoparticles delivery of antisense as lung cancer treatment.
The model was instrumental to demonstrate that nanoparticles could penetrate into tumor
tissue and target telomerase activity, without disturbing adjacent tissue architecture or
inducing significant side-toxicity [76]. PCLS established from human lung tumor tissue
represent therefore a useful in vitro tumor model that has the potential to enhance preclinical
drug evaluation studies. However, an obvious limitation of PCLS is their short lifespan, ~5
days, which prevents long-term exposure, and therefore chronic treatment evaluation.
9. Engineered 3D lung tumor tissues: The OncoCilAir™ model
Tissue engineering is an innovative technology designed at first to produce artificial functional
tissues to repair or replace portion of injured tissues. While initially seen as unrealistic, this
field has made tremendous progress over the past decade, and regenerative medicine will soon
become a routine technique [77]. Today, it is possible by combining human cells with suitable
bioscaffolds to produce in vitro tissue equivalents from many sources (e.g. corneal, cartilage,
intestinal, muscle, respiratory, skin, etc...). More recently, this promising technology has been
applied to the field of oncology with some attempts to develop engineered tumor tissues for
pre-clinical research (e.g. human melanoma model) [78]. Here we took advantage of our tissue
engineering know-how in the respiratory field [79] to develop a complex, but accessible, 3D
lung cancer model: OncoCilAir™ [80, 81]. To this purpose, human primary bronchial cells,
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lung fibroblasts and lung adenocarcinoma cell lines were co-cultured at the air-liquid interface
in a transwell insert (Fig.2). After appropriate differentiation, the system closely reproduces
malignant pulmonary nodules invading a human functional airway epithelium (Fig.3).
Figure 2. Schematic representation of the OncoCilAir™ lung cancer model. OncoCilAir™ is a complex cellular mod‐
el based on the co-culture at the air-liquid-interface of three different human components: bronchial cells, lung fibro‐
blasts and NSCLC cell lines. After 30 days, the cells differentiate into a functional respiratory epithelium which
comprises ciliated cells (pink), goblet cells (blue) secreting mucus (light blue), basal cells (yellow), fibroblasts (brown)
and tumor nodules (green).
Figure 3. Cultured at the air-liquid interface in a convenient 24-wells format (A), the OncoCilAir™ model mimics the
in vivo lung tissue of a patient with characteristic tumour lung nodules (B & magnification in C).
Several properties contribute to make OncoCilAir™ a relevant pre-clinical in vitro alternative:
First, it is a 100% human three-dimensional model which summarizes human tumour-stroma
interactions to assess therapies targeting host-tumor interactions (Fig.4). Second, it is a flexible
system: depending on the cell line used to build its tumour component, OncoCilAir™ offers
the possibility to recapitulate distinct molecular subsets of lung cancers (EGFR, KRAS, etc...)
and thus to simulate patient stratification. Third, it is a bi-competency model: the fact that it
includes both compromised and healthy tissues brings the possibility to experiment simulta‐
neously drug efficacy and drug side-effect within a single culture. Lastly, its long lifespan (>3
months) allows to test chronic treatments and recurrence while reducing animal testing.
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Figure 4. A tumor nodule expanding within the OncoCilAir™ human airway epithelium. Adenocarcima cells GFP+
(green) and human bronchial epithelial cells nuclei DAPI+ (blue) were visualized by confocal laser scanning microsco‐
py. Scale bar represents 100 µm.
Accordingly, a dose response efficacy study with the investigational MEK inhibitors selume‐
tinib and trametinib demonstrated that OncoCilAir™ showed responsiveness to anticancer
drugs in agreement with previously reported data, and therefore can be used as a predictive
tool for anticancer drug evaluation [82].
10. Future perspective
Hanahans and Weinberg highlighted six cancer hallmarks which provide us with a framework
to understand this complex disease. These hallmarks include (i) sustaining proliferative
signaling, (ii) evading growth suppressors, (iii) resisting cell death (iv) enabling replicative
immortality, (v) inducing angiogenesis, and (vi) activating invasion and metastasis [83, 84].
However, in essence, cancer is a genetic disease with germ or autosomal mutations affecting
genes implicated in cell division and/or in tissue integrity. These genetic alterations lead to
unrestricted cell division and formation of a clone of cells which undergo further genetic
changes. Some of these mutations promote features that endow cells with a selective advantage
over normal cells, thus creating a more aggressive subclone with an even higher mutation rate,
eventually leading to tumor formation [85]. The clonal theory has been corroborated by several
decades of cancer researches: we now know that mutation in some specific genes, so-called
oncogenes and tumor supressors, are primary cause for cancers. For lung cancers, the com‐
ponents of EGF signaling, such as EGF receptor and its downstream effectors (KRAS, BRAF,
ALK, etc...) are the main drivers [33]. With the advance in biotechnology, it is now possible to
rapidly identify the underlying mutations of the lung cancers for diagnostics and for person‐
alized treatment.
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Table 2. Current and future in vitro lung cancer models sorted according to cancer hallmarks.
However, a genetic change is only one side of the same coin. It is generally recognized now
that the microenvironment surrounding the cancer cells plays also a crucial role in cancer
development [19, 83, 84]. Indeed, tumor cells have to overcome at least six barriers in order to
become invasive [86]. The extracellular matrix, stroma cells, immune cells, etc... form an
integral part of the tumor, therefore should be taken into account. In fact, not all the cancer
cells can grow in standard cell culture conditions: out of 160 tumors, only 8 Chinese NSCLC
cell lines have been established in culture [47].
Therefore, for tissue engineering, the most important, as well as the most challenging task is
to recreate the in vivo-like tumor micro-environment.
Another important issue is to maintain the heterogeneity of the tumor populations. Despite of
huge progresses made in cancer research, the toll cancer claims in both human lives and funds
spent on health care has been only marginally reduced, and in some cases even increases [87,
88]. One of the reasons for this situation is the drug resistance. The underlying cause is the
heterogeneity of the tumor cells: within a tumor several clones with different mutations may
co-exist. Furthermore, another process termed the community effect may be involved. Studies
have suggested that the ability of a cell to respond to a signal may be enhanced by, or even
dependent on, other neighboring cells reacting in the same way at the same time [89]. This
effect helps to explain the formation of blocks of tissue from sheets of cells, and could be of
widespread occurrence and significance in various morphogenesis processes, including tumor
development. The underlying mechanism of the community effect could be the autocrine or
paracrine positive feedback loops, which have also been suggested and identified during
tumor formation. Several studies have outlined the importance of autocrine IL-6 signaling in
lung and breast cancers. For example, one group found a positive correlation between
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persistently activated tyrosine-phosphorylated STAT3, found in 50% of lung adenocarcino‐
mas, and IL-6. Further investigation revealed that mutant EGFR could activate the oncogenic
STAT3 pathway via upregulated IL-6 autocrine signaling [90].
The fact that most of the cancer cells, even the aggressive ones, cannot grow in culture once
dissociated strongly supports this notion. In other words, all the cancer hallmarks are the
hallmarks of the tumor as a whole, not that of individual cancer cells. This has to be taken into
account during the development of in vitro cancer models.
Table 3. Strengths and weaknesses of the different human in vitro models for lung cancer.
Ideally, in vitro lung cancer models should recapture all the hallmarks of human lung cancer.
Each model has its own strength and weaknesses (Table 3). But depending on the application,
simple models may be more relevant and sufficient. Models can therefore be sorted by
complexity:
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1. Cell lines
2. As simplest 3D model, the tumor spheroids represent already a progress with regarding
to monolayer culture of tumor cell lines or primary tumor cells: the cell-cell interaction is
restored. Stroma cells and or matrix could also be added to better mimic the in vivo
situation.
3. Since the lung tumor cells are located at air-liquid interface, co-culture with the normal
airway epithelial cells and fibroblast cells at air-liquid interface, illustrated by OncoCi‐
lAir™, is another realistic scenario for modeling the lung tumors.
4. In vitro PnP (Plug and Play) models with primary tumor derived from the patient.
In addition, Table 2 summarizes how the current, as well as the future in vitro cancer models
can replicate some or all the cancer hallmarks, their use and limitations for drug development.
Finally, we would like to propose an ideal in vitro lung cancer model based on the above
considerations, so-called in vitro PnP (Plug and Play) model (Fig.5).
Figure 5. Schematic representation of an ideal in vitro PnP (Plug and Play) lung cancer model. A primary tumor
derived from the patient is incorporated into a fully differentiated and healthy airway epithelium and cultured at air-
liquid interface in a setting similar to OncoCilair™ (Mas et al., 2015); Then this co-culture model is plugged into a mi‐
cro-fluidic device with artificial blood/or lymphatic vessels (pink color) containing circulating immune cells (blue
color); liver cells (hepatocytes as spheroids, brown color) can also be integrated into the circuit through the plug num‐
ber 2, providing metabolic capacity of drugs. If needed, other cells/organs can be further inter-connected in similar
way. An input/output plug allows the addition of drug or the uptake of medium for analysis. The lung tissue culture
remains accessible to apical exposure during all the experiment.
A primary tumor derived from the patient is incorporated into a fully differentiated and
healthy airway epithelium and cultured at air-liquid interface, a setting similar to OncoCilair™
[82]. Then this co-culture model is plugged into a micro-fluidic device with artificial blood/or
lymphatic vessels containing circulating immune cells; liver cells (hepatocytes as spheroids)
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can also be plugged into the circuit, providing metabolic capacity of drugs. If needed, other
cells/organs can be further inter-connected in a similar way.
We are convinced that, with the development of new technologies such as microfluidic devices
and 3D bio-printing, such models should quickly emerge and strengthen in vitro pre-clinical
cancer research.
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